8-K: Nordson Reports Record FY25 Results, Strong Q4 & Optimistic FY26 Outlook

Nordson Corporation announced record fiscal year 2025 sales and adjusted earnings per share, alongside a strong fourth quarter performance and optimistic guidance for fiscal year 2026.

Summary

• Fourth quarter 2025 sales increased 1% to $752 million, with adjusted diluted EPS growing 9% to $3.03.
• Full fiscal year 2025 achieved record sales of $2.8 billion, a 4% increase, and record adjusted diluted EPS of $10.24, up 5%.
• EBITDA for the full year reached $900 million, meeting the 2025 Ascend strategy goal.
• Free cash flow for fiscal 2025 was a record $661 million, representing a 136% conversion rate of net income.
• Fiscal year 2026 sales are forecasted to be between $2,830 million and $2,950 million, with adjusted earnings per diluted share in the range of $10.80 to $11.50.
• The company completed the divestiture of its medical contract manufacturing business on September 2, 2025.

Sentiment

Score: 8

Explanation: The company reported record full-year sales and adjusted EPS, exceeded Q4 adjusted EPS guidance, achieved its EBITDA strategic goal, and generated record free cash flow. The outlook for FY2026 is positive with anticipated growth. While there were some organic sales declines in specific segments, the overall financial health and forward-looking statements are strong.

Positives

• Record full fiscal year 2025 sales of $2.8 billion, a 4% increase over the prior year.
• Record full fiscal year 2025 adjusted diluted EPS of $10.24, a 5% increase.
• Strong fourth quarter 2025 adjusted diluted EPS growth of 9% to $3.03, at the high end of guidance.
• Achieved 2025 Ascend strategy goal of $900 million in EBITDA for the full year.
• Record full-year free cash flow of $661 million, with a conversion rate of 136% of net income.
• Medical and Fluid Solutions segment showed strong performance in Q4 2025 with sales up 10% and organic sales up 7%, and a 380 basis point margin increase in EBITDA.
• Maintained gross margins of 55% for the full year.
• Fiscal 2026 guidance projects continued growth in sales ($2,830 to $2,950 million) and adjusted EPS ($10.80 to $11.50).
• Backlog increased 5% to approximately $600 million (excluding divested business), positioning for future growth.
• Balanced capital allocation strategy including share repurchases, dividend payments, and debt reduction.

Negatives

• Fourth quarter 2025 organic sales decreased by 1%.
• Full fiscal year 2025 organic volume decreased by 3%.
• Industrial Precision Solutions segment experienced a 2% sales decrease in Q4 2025, driven by a 4% organic sales decrease and double-digit weakness in polymer processing systems.
• Advanced Technology Solutions segment sales decreased 4% in Q4 2025, with a 5% organic sales decrease, due to fewer deliveries of test and inspection systems (particularly x-ray systems).

Risks

• U.S. and international economic and political conditions.
• Financial and market conditions.
• Currency exchange rates and devaluations.
• Possible acquisitions and the company's ability to successfully integrate them.
• The company's ability to successfully divest or dispose of businesses that do not fit its strategic plan.
• Effects of changes in U.S. trade policy and trade agreements, including changes in tariffs by the U.S. or other nations.
• Effects of changes in tax law.
• Possible effects of events beyond control, such as political unrest, including conflicts in Europe and the Middle East, acts of terror, natural disasters, and pandemics.

Future Outlook

Nordson Corporation anticipates solid growth in fiscal year 2026, with forecasted sales ranging from $2,830 million to $2,950 million and adjusted earnings per diluted share between $10.80 and $11.50. The company expects end markets to inflect positively and is positioned for growth through its Ascend Strategy and NBS Next framework, focusing on strategic capital deployment for acquisitions, share repurchases, dividends, and debt service. First quarter fiscal 2026 sales are projected between $630 million and $670 million, with adjusted earnings per diluted share between $2.25 and $2.45.

Management Comments

• "We had a strong operational finish to fiscal 2025, and I want to thank our teams for delivering value to our customers and shareholders."
• "Adjusted earnings per share increased 9% year-over-year, which was at the high end of our fourth quarter guidance."
• "Importantly, we achieved record EBITDA margin and free cash flow conversion of 128% resulting in continued balanced capital allocation of ongoing share repurchases, dividend payments and further debt reduction."
• "Nordsons winning team delivered strong results in line with the expectations we set at the beginning of the year. This is a significant achievement, particularly in the context of the macroeconomic environment this year."
• "As several of our end markets begin to inflect, we are entering the fiscal year optimistic to deliver solid growth in 2026."
• "We also remain focused on creating value for our shareholders by deploying strategic capital for acquisitions, share repurchases, dividends and debt service."

Industry Context

The company's performance, particularly achieving strong results despite a challenging macroeconomic environment, suggests resilience and effective strategic execution. While some segments faced organic declines (e.g., polymer processing, x-ray systems), growth in medical and fluid solutions indicates diversified strength. The optimistic outlook for 2026, anticipating end market inflection, aligns with broader expectations for recovery in certain industrial sectors. The focus on strategic capital allocation, including acquisitions and debt reduction, positions the company for competitive advantage and market share gains.

Stakeholder Impact

• Shareholders: Positive impact due to record financial results, increased adjusted EPS, strong free cash flow, balanced capital allocation (share repurchases, dividends), and optimistic future guidance.
• Employees: Positive impact from a "winning team" culture and continued growth, though specific employee-related impacts are not detailed.
• Customers: Continued value delivery through differentiated products and a close-to-the-customer business model.
• Creditors: Positive impact from debt reduction and strong financial health.

Next Steps

• Nordson management will provide additional commentary on fourth quarter and full year fiscal 2025 results and outlook during a webcast on Thursday, December 11, 2025, at 8:30 a.m. eastern time.
• Continue implementing the Ascend Strategy and NBS Next growth framework to meet increasing customer demand.
• Deploy strategic capital for acquisitions, share repurchases, dividends, and debt service.

Key Dates

Recommendation

The company has demonstrated consistent strong performance, achieving record sales, adjusted EPS, and free cash flow for fiscal year 2025, exceeding its own guidance for Q4 adjusted EPS and meeting its strategic EBITDA goal. The forward-looking guidance for fiscal year 2026 projects continued growth in both sales and adjusted EPS, indicating a positive trajectory. The balanced capital allocation strategy, including share repurchases and debt reduction, further enhances shareholder value. Despite some organic sales declines in specific segments, the overall picture is one of robust financial health, effective strategic execution, and strong future prospects, making it an attractive investment.

Keywords

Nordson Corporation, NDSN, Fiscal Year 2025 Results, Fourth Quarter 2025, Earnings, Sales, Adjusted EPS, EBITDA, Free Cash Flow, Fiscal 2026 Guidance, Industrial Precision Solutions, Medical and Fluid Solutions, Advanced Technology Solutions, Polymer Processing, Electronics Dispense Systems, Test and Inspection Systems, Capital Allocation, Share Repurchases, Dividends, Debt Reduction, Ascend Strategy, NBS Next, SEC Filing, 8-K